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ABSTRACT
Hypocretin system has been described as one of  the most impor-
tant neurotransmission systems involved in the waking process. 
The system’s lack of  function, caused by mutation or neuron death, 
leads to sharp sleepiness in mammals. It has been proposed that a 
hyperactive hypocretin system can result in hyperarousal episodes 
and insomnia. Hypocretins 1 and 2 are bind to two known receptors 
that are widely distributed in the brain. The current study sought 
to analyze if  either polymorphism in hypocretin receptor 1 or in 
hypocretin receptor 2 are associated to insomnia. We enrolled 83 
insomnia patients, confirmed their clinical insomnia symptoms by 
means of  polysomnographic recordings, comparing single nucleo-
tide polymorphism frequencies in both hypocretin receptors and to 
those from healthy control patients who had no sleep disorders as 
confirmed by two nights of  sleeping records. Our results show no 
association to either receptor polymorphism or insomnia.
Keywords: polymorphism genetic, polymorphism single nucleotide, 
receptors insomnia, sleep.
RESUMO
O sistema de neurotransmissão hipocretinérgico tem sido descrito 
como um dos mais importantes envolvidos no processo de manu-
tenção do alerta. A ausência da função neste sistema, por mutação 
ou morte neuronal, leva à sonolência excessiva em mamíferos. Tem 
sido proposto que um sistema hipocretinérgico hiperativo pode re-
sultar em episódios de alerta e insônia. As hipocretinas 1 e 2 se 
ligam a dois receptores conhecidos e amplamente distribuídos no 
cérebro. No presente estudo, buscamos investigar se existe associa-
ção entre variações genéticas nos receptores das hipocretinas e a 
insônia. Foram incluídos 83 pacientes insones, com sintomas clíni-
cos confirmados por registro polissonográfico e investigadas as fre-
quências de polimorfismos em ambos os receptores de hipocretina 
comparados com uma amostra controle sem distúrbios de sono. 
Nossos resultados não mostraram associação entre polimorfismos 
nestes nos dois receptores com insônia.
sleep dysregulation contribute to the most common sleep dis-
order, insomnia(2,3). Insomnia affects nearly 40% of  women and 
30% of  men in the United States(4). Investigations done in other 
populations have demonstrated a similarly high prevalence of  it 
worldwide. For example, a study performed by Ohayon(5) found 
that 36.3% of  people in the United Kingdom suffered from 
insomnia, based on the DSM-IV criteria. Regarding Brazil, two 
studies (one in a big city and the other in a mid-sized city) found 
that approximately 30% of  the adult population complain of  
insomnia(6,7). Giglio(8) found evidences that 50% of  people have 
insomnia at a minimum frequency of  one episode per week.
In contrast to the “occasional insomnia” experienced by 
most of  the people, insomnia may be a persistent or recurrent 
problem to some(9,10), leading to serious medical complications 
including anxiety, depression and multiple physical ailments(11,12). 
Insomnia diagnosis is based on patients’ subjective reports or 
their sleep patterns. Common symptoms include complaints 
about difficulty in beginning and/or keeping asleep or the pres-
ence of  non-restorative sleep. Non-restorative sleep is a poor 
quality sleeping state that is characterized by the inability to keep 
a high quality of  alertness as well as to keep physical and mental 
well being during daylight, what causes impairment when the 
individual perform regular daily activities(13). There are multi-
ple types of  insomnia, including transient insomnia which can 
last a single night or a few weeks; intermittent insomnia hap-
pens from time to time and chronic insomnia happens at least 
three nights a week over a month or longer. Chronic insomnia 
can be either primary (not related to any medical condition) or 
secondary (caused by some other factor). Causes of  secondary 
chronic insomnia include cancer, asthma, arthritis, drugs, stress, 
mental health problems (such as depression) or a poor sleep 
environment.
Although insomnia is a prevalent sleep disorder, patho-
physiology and brain mechanisms involved in the causative hy-
perarousal during the night remain unknown. An underlying 
vulnerability to acute sleep disturbance and subsequent 
development of  chronic insomnia has been proposed by several 
Descritores: insônia, polimorfismo de nucleotídeo único, 
polimorfismo genético, sono.
INTRODUCTION
Human sleep depends on two major factors; a circadian regulator 
and a homeostatic regulator(1). Hyperarousal and homeostatic 
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investigators(14,15), though relatively little data, regarding specific 
factors that might predispose individuals to insomnia, have been 
identified.
Genetic approaches aiming to study the sleep-wake cycle 
allowed the identification of  several genes involved in sleep 
regulation, however concerning insomnia, it has been more 
difficult.
Insomnia studies examining twins suggest the possibility 
that vulnerability to acute/transient sleep disturbance in 
response to stress may have a familial component(16). Serretti 
et al.(17) hypothesized the possible involvement of  a Clock gene 
polymorphism in depressed insomnia patients once significantly 
higher insomnia recurrences happened to patients who were ho-
mozygous for the C variant of  the T3111C Clock gene poly-
morphism. Another study suggested that the adenosine A2A 
receptor gene could be involved in insomnia pathophysiology(18).
Hypocretins are hypothalamic neuropeptides tightly 
associated to wake/sleep cycle(18,19) regulation. The hypotha-
lamic hypocretin system is comprised by neurons that syn-
thesize pre-propeptides that form hypocretin-1 (Hcrt-1) and 
hypocretin-2 (Hcrt-2), such neuropeptides act through two 
G- protein coupled receptors; Hypocretin receptor 1 and 2 
(Hcrtr1 and Hcrtr2)(20,21,22). Receptors genes were mapped on 
human chromosome 1p33 (Hcrtr1) and 6cen (Hcrtr2) and 
each receptor gene was found to have seven coding exons with 
conserved splice junction positions across species(23).
Because hypocretins are involved in wakefulness 
maintenance, they are natural candidates to be involved to 
insomnia. Although small in number, neurons containing this 
neurotransmitter are strongly associated to arousal and receive 
abundant input from the limbic system(19,24). This association 
might be important for increasing arousal during emotional 
stimuli as it is the case during insomnia. Hypocretin’s release 
into locus coeruleus and raphe nuclei is required such wake-promoter 
neuronal areas sustained activation and help stabilizing the sleep 
to wake switch, thus preventing intermediate states and inap-
propriate transitions between cycles(24).
Recent studies on zebrafish have shown that hypocretin 
overexpression promotes and consolidates wakefulness and in-
hibits rest, just as in insomnia(25,26). Accordingly, Perlis(27) suggests 
that insomnia is a hyperarousal disorder in which the patient 
has an alertness level that is incompatible to sleep initiation or 
maintenance. Such hyperarousal is inherent to the insomnia and 
therefore it is reasonable to infer that alterations in neurotrans-
mission of  the postero-lateral hypothalamus, also considered 
brain’s wake center, could be - at least in part - responsible for 
insomnia(28). Reduced sleep time and increased nocturnal awak-
enings may be related to an increase on circulating hypocretin 
levels throughout the night(29).
There are few studies on genetics of  insomnia showing 
that, possibly, gene polymorphisms involved in sleep regulation 
could generate or predispose people to such medical condition. 
Because of  the great involvement of  hypocretin in sleep regula-
tion, receptors involved in the hypocretin system gene polymor-
phisms are prime targets when searching genes involved with 
insomnia. The current study analyzed two informative, non-
synonymous single nucleotide polymorphisms (SNPs) in Hcrtr1 
and Hcrtr2 in a group of  insomniac patients.
MATERIAL AND METHODS
Subjects
The control group was composed by 74 subjects with mean age 
of  35 ± 11 years old, and a body mass index (BMI) of  24.1 
± 4.1. Fifty-four percent of  the control subjects were women 
and 67% were Caucasian. Subjects who had any sleep distur-
bances (as confirmed in basal polysomnography), subjects that 
used medicines capable of  modifying (inducing or reducing) 
physiological sleep, or subjects with other health issues, and 
those having a blood relationship with another volunteer were 
excluded prior to the beginning of  the study.
The insomnia group included 83 patients (mean age 52 
± 13 years, BMI 24.1 ± 5.0, 67% women and 68% Caucasian) 
that were submitted to an interview and were judged in order to 
meet the criteria of  primary insomnia(30) at the Sleep Institute, 
São Paulo, Brazil. Judging criteria required that patients had 
at least three insomnia nights a week, and that their sleep 
disturbances had a significantly negative impact on subjects’ 
social and professional lives(31). Exclusion criteria included pa-
tients having any other sleep disturbance besides insomnia, or 
any patient who was blood relative to another volunteer.
At a glance, 157 people took part in the experiment, 83 
of  whom had insomnia and 74 were controls that did not have 
any sleep disorder.
Polysomnographic recordings
Polysomnograms were taken throughout a night of  sleep from 
the experimental group members aiming to confirm their sleep 
complaints and to obtain measurements of  their sleep patterns. 
Two nights of  sleep from the control group were analyzed, includ-
ing one habituation night, so patients could get used to sleeping 
in the laboratory, and a subsequent test night. All subjects were 
requested to be at the sleep laboratory by 20:00h, but went to 
bed at their usual bedtime and were told to avoid daytime naps 
(except when diurnal sleep was usual for the subject). Alcohol 
consumption was not allowed and caffeine was restricted to one 
cup a day, in the morning. Control subjects were submitted to 
the same recording conditions, in the same laboratory settings as 
the experimental group. During habituation night, the absence 
of  other sleep disorders (sleep apnea syndrome, etc.) was con-
firmed both for control and insomnia patients.
Sleep parameters
Sleep stages were tabulated for 30-second epochs using the Re-
chtschaffen and Kales International scoring manual(32). The fol-
lowing sleep parameters were analyzed: total sleep time (TST), 
sleep efficiency (as described by dividing TST by the total record-
ing time), sleep latency (as defined by the first three consecutive 
epochs of  any sleep stage), REM latency (time from sleep onset 
to the first epoch of  REM sleep), number of  arousals (16 s or 
longer) and its index per hour of  sleep, wake time after sleep 
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onset (WASO), the REM, NREM sleep and the sleep time per-
centage taken by its four stages (stages 3 and 4 were condensed 
together and called delta sleep).
Genotyping the polymorphisms in hypocretin receptors 
1 and 2
Blood samples were collected from all participants in the 
experiment and DNA was extracted from the white cells. 
Genotyping was performed using PCR-RFLP and PCR prod-
ucts for polymorphisms, in both receptors, were digested by 
BccI (New England Biolabs, USA) at 37°C for three hours. 
The fragment (280-bp) containing hypocretin receptor 1 
SNP G1222A (rs2271933) was amplified using designed for-
ward primer 5’-ATTCCGGGAGCAGTTTAAGG-3’ and 
the reverse primer 5’-GATGAAGCCACAGCCTTTC-3’. 
Regarding hypocretin receptor 2 SNP G922A (rs2653349), 
the amplification of  a 330-bp product was achieved by for-
ward primer 5’-AGAGAAAATGGAAGCCCCTG-3’ and 
the reverse primer 5’-AGTCATCTGGCCTGACAAGG-3’. 
Digestion fragments were analyzed via electrophoresis on a 
2% agarose gel.
Statistical analysis
Groups’ genotypic frequencies were compared using a χ2 
analysis. Hardy-Weinberg equilibrium was verified in the 
control and in the insomnia groups as well. Polysomnographic 
parameters were compared using a Student t or Mann-Whitney 
test with significance levels set at p = 0.05.
Ethics issues
All the participants signed an informal consent and the study 
was approved by UNIFESP Ethics Committee, approval 
nº 0484/04.
RESULTS
Polysomnographic recordings
Sleep parameters’ analysis showed that the patients who com-
plained of  insomnia have high deleterious polysomnographic 
parameters indicating high alertness and poor restorative sleep 
throughout the night (Table 1).
Sleep parameters observed in the control group are 
within the expected values for a sample of  healthy subjects 
without sleep disorders. However, sleep parameters observed in 
the insomniac experimental group corroborate data described in 
the literature(30). It was confirmed that the experimental group 
had reduced total sleep time, increased latency of  sleep onset 
or REM sleep in relation to the control group. There was also a 
wake time increase after sleep onset and the index of  awakenings, 
demonstrating that the experimental group had difficulty in 
initiating sleep or reinitiating sleep after waking during the night, 
thus jeopardizing sleep efficiency (72.9 ± 0.9%; p < 0.01). Statis-
tically significant differences found between the control group 
and the insomnia group as well as the absence of  any other sleep 
disorders, show that individuals who took part in the current 
experiment were correctly diagnosed as insomniac.
Table 1. Control and insomniac groups’ sleep measurement.
Sleep Parameters Control Group (n = 74) Insomniac Group (n = 83)
Sleep latency (min) 10.2 ± 0.9 49.5 ± 2.3*
REM latency (min) 82.4 ± 3.8 150.0 ± 7.4*
TST (h) 6.3 ± 0.1 4.9 ± 0.1*
Sleep efficiency (%) 92.1 ± 0.0 72.9 ± 0.9*
Stage 1 (%) 2.4 ± 0.1 7.3 ± 0.5*
Stage 2 (%) 57.8 ± 0.5 61.3 ± 1.1*
Stage Delta (%) 19.2 ± 0.6 16.4 ± 0.8*
REM stage (%) 20.3 ± 0.6 14.9 ± 0.8*
WASO (%) 26.8 ± 1.6 109.1 ± 4.6*
Arousal # 59.1 ± 2.7 82.0 ± 5.0*
Arousal index 9.3 ± 0.4 16.4 ± 0.9*
Sleep latency: Falling asleep (in minutes); REM Latency: Falling into REM sleep (in 
minutes); TST: Total sleep time (in hours); Sleep efficiency: Percentage of  time asleep 
throughout the night; Stages 1, 2, and delta: Percentage of  time in each stage of  slow-
wave sleep; REM stage: Percentage of  the time elapsed in REM sleep; WASO: Wake 
time after sleep onset; Number of  arousals that have occurred throughout the night; 
Arousal index (Arousals/Total Sleep Time). Values expressed as mean ± standard 
error. Student t test was performed; * indicates that p < 0.05.
Aiming to explore whether insomnia sleep parameters 
were different in males and females we analyzed both genders 
separately, as seen in Table 2. When comparing the main sleep 
parameter differences between insomniac males or insomniac 
females to their respective controls, we observed that female 
individuals have a much more increased latency to the first REM 
episode while they exhibit no sharp differences in the second 
and in delta stages.
Genotyping the polymorphisms in hypocretin 
receptors 1 and 2
Receptor 1 polymorphism G1222A
The genotypic frequencies observed in the control group and 
in the insomniac group are shown in Table 3 for the hypocretin 
receptor 1 polymorphism. We do not observe statistically 
significant differences between the two groups. Once insomnia 
was more prevalent in female subjects we also have analyzed 
individuals separated by gender and no differences were found 
(data not shown).
Receptor 2 polymorphism G922A
The genotypic frequencies observed in the control and in the 
insomniac groups are shown in Table 4. We do not observe any 
statistically significant differences between groups in regards 
to polymorphism, even when analyzing samples separated 
by gender.
DISCUSSION
A strong genetic basis for normal sleep has been shown in both 
humans and animals. Studies due to normal human adults indi-
cate that slow wave sleep rates are strongly influenced by genetic 
factors. It can be estimate a 50% heritability average, which 
is higher than most other human traits. In addition, several 
sleep disorders have familial or genetic and environmental 
components(33).
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Table 2. Control and insomniac groups by gender sleep measurements.
Male Female
Parameters Control (n = 36) Insomniac (n = 32) Control (n = 38) Insomniac (n = 51)
Sleep Lat (min) 9.1 ± 1.3 49.9 ± 3.6* 11.1 ± 1.4 49.2 ± 3.0*
REM Lat (min) 79.5 ± 6.1 120.3 ± 7.0* 85.1 ± 4.7 168.1 ± 10.3*
TST (h) 6.2 ± 0.1 5.1 ± 0.1* 6.3 ± 0.1 4.7 ± 0.1*
Sleep effic (%) 92.7 ± 0.5 73.1 ± 1.4* 91.4 ± 0.5 72.7 ± 1.3*
Stage 1 (%) 2.7 ± 0.2 6.8 ± 0.8* 2.2 ± 0.1 7.6 ± 0.6*
Stage 2 (%) 57.4 ± 0.9 63.1 ± 1.7* 58.1 ± 0.7 60.1 ± 1.4
Stage Delta (%) 18.4 ± 0.9 14.8 ± 1.1* 20.0 ± 0.8 17.3 ± 1.1
REM stage (%) 21.3 ± 0.8 15.0 ± 1.3* 19.4 ± 0.9 14.8 ± 1.1*
WASO 25.4 ± 2.2 114.3 ± 7.6* 28.2 ± 2.3 105.9 ± 5.8*
Arousal # 62.7 ± 4.1 91.0 ± 9.2* 55.7 ± 3.5 76.4 ± 5.8*
Arousal index 9.9 ± 0.6 17.4 ± 1.4* 8.6 ± 0.5 15.9 ± 1.1*
Sleep latency: Falling asleep (in minutes); REM Latency: Falling into REM sleep (in minutes); TST: Total sleep time (in hours); Sleep Efficiency: Percentage of  the time in sleep 
throughout the night; Stages 1, 2, and delta: Percentage of  time in each stage of  the slow-wave sleep; REM stage: Percentage of  the time elapsed in RIM sleep; WASO: Wake time 
after sleep onset; Number of  arousals throughout the night; Arousal index (Arousals/Total Sleep Time). Values expressed as mean ± standard error. Student t test was performed 
for analysis. * p < 0.05.
Table 3. Genotypic frequencies of  the receptor 1 polymorphism.
Genotypes Control Group (n) Insomniac Group (n)
AA 0.14 (10) 0.10 (8)
GA 0.58 (43) 0.66 (55)
GG 0.28 (21) 0.24 (20)
n = number of  individuals.
Table 4. Genotypic frequencies of  the hypocretin receptor 2 polymorphism.
Genotypes Control Group (n) Insomniac Group (n)
AA 0.03 (2) 0.01 (1)
GA 0.26 (19) 0.22 (18)
GG 0.72 (53) 0.77 (64)
n = number of  individuals.
The hypocretin system is one of  the major arousal 
systems in the brain and it is a potential site for genetic vari-
ations identifications associated to insomnia. Recent data in 
a zebrafish model of  sleep show that a null mutation in the 
hypocretin receptor causes a sleep/wake pattern that resembles 
insomnia(26). However, in our study, no association was observed 
between either hypocretin receptor 1 or hypocretin receptor 2 
and insomnia.
The observation of  our results suggest that the non-
synonymous polymorphisms found In hypocretin receptors do 
not affect hypocretin neurotransmission or perhaps our sample 
size is not large enough to reveal an association. Significant as-
sociations among other hypocretin receptor polymorphisms 
(besides the ones studied here) and cluster headaches have been 
reported(34,35). It is thus a worthwhile endeavor to further explore 
these polymorphisms and their relationship to sleep, since there 
is a reciprocal relationship between sleep and headaches(36).
Another hypocretin neurotransmission area that should 
be examined by further genetic studies is hypocretin’s synthesis 
and release. It may be the key element producing the waking 
state, instead of  receptors.
One of  the deepest difficulties faced when study-
ing insomnia is the problem of  identifying endophenotype. 
Different endogenous brain processes can lead to insomnia and 
a too heterogeneous group comprised of  insomniacs without 
similar insomnia causes can hamper proper genetic analysis. 
Based on our sample, we could realize that despite our efforts 
to control it, insomnia profiles are not the same in all patients. 
Some of  the patients have lengthy sleep latency, while others 
wake too often during the night. More rigid group stratification 
may be needed in order to achieve positive results.
The search for candidate genes to understand primary in-
somnia has not yet yielded satisfactory results, most likely due to the 
disease’s complex nature. The causes of  sleep loss are many. In spite 
of  the negative results from our study, hypocretin system still holds 
great promise for a possible association to insomnia. Additional 
studies with larger samples, more rigid criteria for patient stratifica-
tion and a search for new polymorphisms involved in hypocretin 
synthesis and release machinery are important future steps.
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